CA
NZ
UK
AU
IND
US
ProMIS Neurosciences Inc. has reported an adjusted earnings per share of $-1.26 for the quarter ending March 31, 2026, significantly better than the anticipated consensus estimate of $-1.49. This positive variance has fueled enthusiasm among investors.
Aptevo Therapeutics Inc. (NASDAQ: APVO) has secured a provisional patent covering a Nectin‑4 × PD‑L1 dual‑targeting backbone, broadening its solid‑tumor portfolio beyond a single investigational product. The filing protects a core molecular architecture that can be adapted for a range of therapeutic formats, including …
Camp4 Therapeutics Corp (NASDAQ: CAMP) has secured a significant funding opportunity after receiving regulatory clearance for its clinical trial. This development is a notable milestone for the company, as it progresses in its efforts to develop innovative treatments for genetic diseases. The clearance paves …
Bristol Myers Squibb (NYSE: BMY) has drawn notable attention as Izzy Englander, a prominent hedge fund manager with a net worth nearing $25.8 billion, significantly increased his stake in the company by a staggering 780% during the first quarter of 2026. This substantial repositioning …
Cosmos Health Inc. has unveiled a subscription platform customized for health products, marking a significant step in enhancing its service offerings. This strategic initiative aims to cater to a growing consumer demand for convenient access to healthcare solutions. However, the announcement comes at a …
Unprecedented Revenue Growth for Alnylam
Veru Inc. (NASDAQ:VERU) is betting its oral drug enobosarm can fix a side effect of GLP-1 weight-loss drugs: the loss of muscle alongside fat. Phase 2b data paired with semaglutide showed lean-mass preservation and greater fat loss, and Veru is now running a follow-on …
TELA Bio, Inc. (NASDAQ:TELA) continues widening its OviTex soft-tissue reconstruction lineup, adding a fully resorbable hernia-repair option in April 2026 even as first-quarter revenue growth slowed to single digits. With operating expenses held flat, a new $70 million Perceptive term loan and a refreshed …
Tenon (NASDAQ:TNON) Medical is expanding its sacroiliac joint fusion franchise around the Catamaran and SImmetry+ systems, and its first-quarter 2026 results showed real traction: revenue nearly doubled and gross margin jumped 24 points. The same filings disclose a going-concern warning, two active Nasdaq listing …
Silexion Therapeutics Corp. (NASDAQ:SLXN) said on June 23, 2026, that Germany's federal drug regulator, BfArM, unconditionally approved its clinical trial application for a Phase 2/3 study of SIL204 in locally advanced pancreatic cancer, backed by a positive ethics opinion. The clearance follows Israeli authorization …
Please wait processing your request...